Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Matritech raises $6.56 million to step up IVD (in vitro diagnostic) work:

This article was originally published in Clinica

Executive Summary

Matritech, of Newton, Massachusetts, has sold common stock and warrants in a private placement that raised $6.56m, or $5.85m net. The diagnostic proteomics company says the funds will be used to increase marketing and sales efforts, as well as for ongoing in vitro diagnostic development, clinical trials, working capital, capital expenditures and general corporate purposes. Matritech has two approved products for diagnosing and monitoring bladder cancer, and has discovered proteins associated with cervical, prostate, breast and colon cancer.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts